College of Pharmacy
View Related Pages
HelixTalk
View Related Pages
This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics. We're hoping that our real-life clinical pearls and discussions will help you stay up-to-date and improve your pharmacy knowledge.
How Do I Listen?
HelixTalk is available via Apple Podcasts (or by searching for HelixTalk), by subscribing to our RSS feed, subscribing to our mailing list, or by listening to any episode in your browser (below).
HelixTalk Episodes
HelixTalk #192 - Opioids Optional: Journavx, the New Acute Pain Management Alternative
Date posted: July 23, 2025, 6:00 am
In this episode, we discuss the evidence, safety, and place in therapy of Journavx® (suzetrigine), a newly approved analgesic with a unique non-opioid mechanism of action and additional considerations for its use.
HelixTalk #191 - The Ultimate Guide to ARBs: An In-depth Drug Class Review
Date posted: June 23, 2025, 6:00 am
In this episode, we review the pharmacology, indications, adverse effects, monitoring, and unique drug characteristics of angiotensin receptor blockers (ARBs).
HelixTalk #190 - Can’t Stop, Won’t Drop … The BP That Just Won’t Quit: Diagnosis and Treatment of Resistant Hypertension
Date posted: May 29, 2025, 2:10 pm
In this episode, we discuss the diagnosis and treatment of resistant hypertension, including a newer endothelin receptor antagonist (ERA) called aprocitentan (Tryvio®).
HelixTalk #189 - Mice, Macrophages, and Metabolism: Browning Keeps Obesity at Bay
Date posted: April 7, 2025, 8:35 am
In this episode, we discuss the very early stages of drug targets and drug development with Dr. Mohd Shahid, PhD. Dr. Shahid’s research involves the IER3 gene, which is an important modulator of the body’s inflammatory response via its action in major immune cells, including macrophages and T-cells, and plays a role in metabolic disorders such as obesity, diabetes, and atherosclerosis, revealing a previously unknown function of this protein.